Drugs targeting human epidermal growth factor receptor-2 (HER-2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) have provided gastric cancer patients with better survival rates [29, 30]. This evidence concerns the gene ERBB2 and gastric cancer.